HC Wainwright Decreases Earnings Estimates for Altimmune

Altimmune, Inc. (NASDAQ:ALT) – Research analysts at HC Wainwright reduced their FY2024 earnings per share estimates for Altimmune in a report released on Wednesday, November 13th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($1.28) per share for the year, down from their previous forecast of ($1.25). HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Altimmune’s current full-year earnings is ($1.36) per share. HC Wainwright also issued estimates for Altimmune’s Q1 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.33) EPS, FY2025 earnings at ($1.32) EPS, FY2026 earnings at ($1.45) EPS, FY2027 earnings at ($1.45) EPS and FY2028 earnings at ($0.15) EPS.

Several other brokerages have also issued reports on ALT. UBS Group began coverage on Altimmune in a research note on Tuesday, November 12th. They set a “buy” rating and a $26.00 price target on the stock. Evercore ISI raised shares of Altimmune to a “strong-buy” rating in a research note on Friday, August 9th. Finally, B. Riley reissued a “buy” rating and issued a $20.00 price target on shares of Altimmune in a report on Monday, August 12th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $20.00.

Altimmune Stock Performance

Shares of ALT stock opened at $7.61 on Monday. The stock’s fifty day moving average is $7.02 and its 200-day moving average is $6.91. Altimmune has a 52 week low of $2.34 and a 52 week high of $14.84. The stock has a market capitalization of $541.22 million, a PE ratio of -4.91 and a beta of 0.09.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.03. The firm had revenue of $0.01 million for the quarter. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. During the same period in the prior year, the company posted ($0.39) earnings per share.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in ALT. Geode Capital Management LLC increased its holdings in Altimmune by 4.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,668,004 shares of the company’s stock worth $10,244,000 after purchasing an additional 74,194 shares in the last quarter. Barclays PLC raised its holdings in Altimmune by 93.0% in the 3rd quarter. Barclays PLC now owns 155,741 shares of the company’s stock valued at $956,000 after buying an additional 75,064 shares during the last quarter. Wellington Management Group LLP grew its holdings in Altimmune by 27.5% during the 3rd quarter. Wellington Management Group LLP now owns 197,232 shares of the company’s stock worth $1,211,000 after acquiring an additional 42,553 shares during the last quarter. Stifel Financial Corp increased its position in Altimmune by 77.4% in the 3rd quarter. Stifel Financial Corp now owns 17,752 shares of the company’s stock valued at $109,000 after acquiring an additional 7,746 shares during the period. Finally, Centiva Capital LP acquired a new position in shares of Altimmune during the third quarter worth $120,000. Institutional investors own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.